Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Denali Therapeutics Inc. (DNLI) had Return on Equity of -50.56% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-512.54M |
|
-- |
|
-- |
|
$555.34M |
|
$-555.34M |
|
$42.90M |
|
$-512.44M |
|
$-512.44M |
|
$-512.54M |
|
$-512.54M |
|
$-512.54M |
|
$-512.54M |
|
$-555.34M |
|
$-554.41M |
|
172.65M |
|
172.65M |
|
$-2.97 |
|
$-2.97 |
|
| Balance Sheet Financials | |
$900.66M |
|
$52.40M |
|
$244.20M |
|
$1.14B |
|
$98.35M |
|
$5.53M |
|
$32.74M |
|
$131.09M |
|
$1.01B |
|
$1.01B |
|
$1.01B |
|
156.18M |
|
| Cash Flow Statement Financials | |
$-412.60M |
|
$255.28M |
|
$189.22M |
|
$176.53M |
|
$208.43M |
|
$31.90M |
|
$99.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.16 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-422.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-50.56% |
-50.56% |
|
-44.77% |
|
-50.28% |
|
$6.49 |
|
$-2.44 |
|
$-2.39 |
|